BioSpace News Archive

Prana Thoracic, Inc., today announced that Nucore Medical, Inc., the company’s wholly owned subsidiary has been awarded a $3M grant from the Cancer Prevention and Research Institute of Texas (“CPRIT”).

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators, announced the grant of inducement restricted stock units to acquire 17,300 shares of Albireo’s common stock.

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the “Notice”) on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising Biocept that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1).

Becton, Dickinson and Company (NYSE: BDX) (the " Company " or " BD ") today announced the consideration payable in connection with its previously announced Tender Offers (as defined below) to purchase for cash up to $500,000,000 aggregate principal amount.

Takeda (TSE:4502/NYSE:TAK) today announced the company’s dengue vaccine, QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the Indonesia National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan (BPOM), for the prevention of dengue disease caused by any serotype in individuals six years to 45 years of age.

According to Vision Research Reports, the acute external ventricular drain market size was estimated at around USD 218.84 million in 2021 and it is projected to hit around USD 432.97 million by 2030, growing at a CAGR of 7.88% from 2022 to 2030

Drug discovery and development is a cost-intensive and time-consuming process.

The global clinical investigative site network market is anticipated to reflect a considerable growth rate across the forecast period.

According to Report, the global high-performance liquid chromatography market was surpassed at USD 4.31 billion in 2021 and is expected to hit around USD 7.26 billion by 2030, growing at a CAGR of 5.96% from 2022 to 2030

Non-opioid analgesics have broad applications in treating mild or severe pain, including pain associated with musculoskeletal, surgical, trauma, cancer, or other types of pain.